Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus (Q34717929)

4 August 2017

1 reference

title

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus (English)

1 reference

4 August 2017

0 references

Kjeld Hermansen

1

1 reference

PubMed ID

18035865

4 August 2017

Lene S Mortensen

series ordinal

2

1 reference

4 August 2017

1 January 2007

1 reference

4 August 2017

1 reference

4 August 2017

30

1 reference

4 August 2017

1127-1142

1 reference

4 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200730120-00005

4 August 2017

0 references

cites work

Current estimates of the economic cost of obesity in the United States

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730120-00005

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730120-00005

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730120-00005

alpha-Glucosidase inhibitors

21 January 2018

1 reference

12 December 2020

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

12 December 2020

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia

1 reference

12 December 2020

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

12 December 2020

One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

1 reference

12 December 2020

Is continued weight gain inevitable in type 2 diabetes mellitus?

1 reference

12 December 2020

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

1 reference

12 December 2020

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

1 reference

12 December 2020

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

12 December 2020

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

12 December 2020

Tissue selectivity of insulin detemir action in vivo.

1 reference

12 December 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

12 December 2020

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients

1 reference

12 December 2020

Does insulin detemir have a role in reducing risk of insulin-associated weight gain?

1 reference

12 December 2020

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

12 December 2020

Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.

1 reference

12 December 2020

Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

12 December 2020

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

1 reference

12 December 2020

Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women

1 reference

12 December 2020

Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

Weight gain during insulin therapy in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Dynamics of insulin secretion in obesity and diabetes

1 reference

12 December 2020

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

1 reference

12 December 2020

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

1 reference

12 December 2020

Diabetes, obesity, and the brain

1 reference

12 December 2020

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

1 reference

12 December 2020

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Use of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Improving the adverse cardiovascular prognosis of type 2 diabetes

1 reference

12 December 2020

Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

1 reference

12 December 2020

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

1 reference

12 December 2020

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

1 reference

12 December 2020

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

1 reference

12 December 2020

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

1 reference

12 December 2020

Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care

1 reference

12 December 2020

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

12 December 2020

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

1 reference

12 December 2020

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

1 reference

12 December 2020

Mechanisms of nutritional and hormonal regulation of lipogenesis

1 reference

12 December 2020

Obesity and disease management: effects of weight loss on comorbid conditions

1 reference

12 December 2020

Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients.

1 reference

12 December 2020

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

12 December 2020

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

1 reference

12 December 2020

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

1 reference

12 December 2020

Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

12 December 2020

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Inhibition of central amylin signaling increases food intake and body adiposity in rats

1 reference

12 December 2020

Recent findings concerning thiazolidinediones in the treatment of diabetes

1 reference

12 December 2020

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

1 reference

12 December 2020

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

1 reference

12 December 2020

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

1 reference

12 December 2020

Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus.

1 reference

12 December 2020

Treatment of hypertension in diabetes

1 reference

12 December 2020

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

12 December 2020

Intentional weight loss and mortality among overweight individuals with diabetes.

1 reference

12 December 2020

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

1 reference

12 December 2020

Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes

1 reference

12 December 2020

The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

Insulinotropic meglitinide analogues

1 reference

12 December 2020

Combination therapies with insulin in type 2 diabetes

1 reference

12 December 2020

Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.

1 reference

12 December 2020

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

12 December 2020

A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Failure of adipocyte differentiation causes type II diabetes mellitus?

1 reference

12 December 2020

New insulins in the treatment of diabetes mellitus

1 reference

12 December 2020

Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

12 December 2020

When oral agents fail: practical barriers to starting insulin

1 reference

12 December 2020

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

1 reference

12 December 2020

Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.

1 reference

12 December 2020

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

12 December 2020

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance

1 reference

12 December 2020

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

1 reference

12 December 2020

Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.

1 reference

12 December 2020

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

1 reference

12 December 2020

Obesity, weight loss and prognosis in type 2 diabetes.

1 reference

12 December 2020

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

1 reference

12 December 2020

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

12 December 2020

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.

1 reference

12 December 2020

Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion

1 reference

12 December 2020

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

12 December 2020

Mechanisms for weight gain during blood glucose normalization

1 reference

12 December 2020

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

12 December 2020

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

1 reference

12 December 2020

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

12 December 2020

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

1 reference

12 December 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

1 reference

12 December 2020

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

1 reference

12 December 2020

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

12 December 2020

10.2165/00002018-200730120-00005

Identifiers

DOI

1 reference

PubMed ID

18035865

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

18035865